AVANIR Pharmaceuticals Announces Last Patient Enrolled In Neuropathic Pain Phase III Trial With Zenvia

SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.